Dr Waleed Mohammed : Clinical oncology

Home
Dr Waleed Mohammed

Bupa Platinum consultant
Fee assured
Verified account
Open Referral network

Overview

Specialises in

Brain/CNS

Lung

Offers

Face-to-face consultations
Video and telephone consultations

About me

Dr Mohammed initially trained as a bio-scientist, specializing in genetics at the University of Cambridge and completing an MSc in biology at the University of Oxford, before delving into the pharmaceutical industry (Oxford Science Park and MRC Prion Unit at Queen Square, University College London).

He subsequently re-trained as a medic (Cambridge Graduate Course in Medicine), specializing in clinical oncology, undertaking specialist registrar training at Imperial College NHS Trust, The Royal Marsden Hospital and The Royal Sussex County Hospital. He has been a consultant clinical oncologist at Charing Cross Hospital since 2020, where he introduced, developed and established the SABR radiotherapy service.

He is a member of The Royal College of Physicians (London) and a Fellow of The Royal College of Radiologists (New Fellows Speaker award).

Areas of interest

Primary and secondary thoracic cancers (NSCLC, SCLC, LCNET, mesothelioma and thymic cancers); primary and secondary CNS (brain and spine) cancers (LGG, HGG, meningioma, ependymoma, medulloblastoma, pituitary tumours, pineal tumours and intra-cranial germ cell tumours); Cytotoxic Systemic Anti-Cancer Therapy (SACT), Immunotherapy/Check-Point Inhibitors (IO/CPI), Oral Tyrosine Kinase Inhibitors (TKI); Linac-based palliative/radical External Beam Radiotherapy (EBRT), Linac-based Stereo-tactic Ablative Radiotherapy (SABR), MR-Linac (MRL) SABR, Linac-based Stereotactic Radiosurgery (SRS), Gamma Knife based SRS (including frame-fitting) and Optune Tumour Treating Fields (TTF).

Medical secretaries

Claire Farrell
Charing Cross Hospital Fulham Palace Road London W6 8RF
020 3311 8427
020 3311 8427
claire.farrell7@nhs.net

About me

Current NHS consultant posts held

Charing Cross Hospital, Fulham Palace Rd, London, W6 8RF

Research interests

Early in his career as a geneticist, Dr Mohammed was involved in research elucidating the role of newly discovered genes in development of the early mouse embryo. He was also focused on investigating the biology of lysosomal storage disorders and prion disease in order to develop drug therapy.

As an oncology trainee, he investigated the short-term toxicity of brachytherapy in prostate cancer patients with inflammatory bowel disease, and was awarded first prize for best presentation at international conference level.

As a consultant, he is sub-investigator on a number of clinical trials, and has been focused on service development within the oncology department at Charing Cross Hospital, and most recently established and leads the new SABR radiotherapy service.

Awards received

He is a member of The Royal College of Physicians (London) and a Fellow of The Royal College of Radiologists (New Fellows Speaker award).

(Additional) Languages spoken

Publications

PKorolewicz JA, Scheiner B, Fulgenzi CAM, D'Alessio A, Cortellini A, Pascual C, Mehan A, Partridge S, Gujral DM, Mohammed W, Mohammed O, Grzesiak A, Booker L, Cleator S, Pokrovska T, Saleem W, Rackie J, Needham Y, Krell J, McNeish I, Tookman L, Park WE, Asif M, Evans JS, Pinato DJ. The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden. Chemotherapy. 2024 Apr 27:1-7. doi: 10.1159/000539109. Epub ahead of print. PMID: 38679017

Hamish Sinclair, Kerlann Le Calvez, Jiarong Chen, Lillie Pakzad-Shahabi, Luke Dixon, Waleed Mohammed, Waqar Saleem, Matthew Williams, Estimating population-based incidence of brain metastases – a comprehensive incident cohort study, Neuro-Oncology, Volume 23, Issue Supplement_4, October 2021, Page iv21, https://doi.org/10.1093/neuonc/noab195.053

Seema Dadhania, Lillie Pakzad-Shahabi, Kerlann Le Calvez, Waqar Saleem, James Wang, Waleed Mohammed, Sanjay Mistry, Matthew Williams, BrainWear: Longitudinal, objective assessment of physical activity in 42 High Grade Glioma (HGG) patients, Neuro-Oncology, Volume 23, Issue Supplement_4, October 2021, Page iv3, https://doi.org/10.1093/neuonc/noab195.006

Mohammed W, Hoskin P, Henry A, Gomez-Iturriaga A, Robinson A, Nikapota A. Short-term Toxicity of High Dose Rate Brachytherapy in Prostate Cancer Patients with Inflammatory Bowel Disease. Clin Oncol (R Coll Radiol). 2018 Sep;30(9):534-538. doi: 10.1016/j.clon.2018.06.007. Epub 2018 Jun 30. PMID: 30099986

My qualifications & training

Qualifications

BA Natural Sciences (Part 2 Genetics) University of Cambridge 2003
MBBChir (Graduate Medicine) University of Cambridge 2010
MSc Integrative Biosciences (Biology) University of Oxford 2004
Member of The Royal College of Physicians The Royal College of Physicians (London) 2014
Post-Graduate Diploma in Oncology London University (Institute of Cancer Research) 2016
Fellow of The Royal College of Radiologists The Royal College of Radiologists (London) 2019

GMC registration

Reference number 7080302

Information for healthcare professionals (Bupa patients only, last 12 months)

Procedures completed

A1080
Stereotactic radiotherapy (SRT), second to fifth sessions, including adjustments, using Cyberknife or similar SRT technology - (1-5)

Cromwell Hospital (1-5)
X6930
Clinical supervision of the planning of a course of complex radiotherapy - (1-5)

Cromwell Hospital (1-5)
A0380
Stereotactic radiotherapy (SRT) using GammaKnife or similar SRT technology - (1-5)

Cromwell Hospital (1-5)
X6950
Clinical supervision of the planning of stereotactic radiosurgery e.g. SRT/SBRT and Gamma Knife - (1-5)

Cromwell Hospital (1-5)
A1070
Stereotactic radiotherapy (SRT), first/sole session using Cyberknife or similar SRT technology - (1-5)

Cromwell Hospital (1-5)
X0007
Clinical supervision of external beam radiotherapy, up to and including 15 fractions or part thereof - (1-5)

Cromwell Hospital (1-5)

Report this page

Finder

Note: